Background
==========

Malaria is the most important imported tropical disease and responsible for most deaths that occur among individuals returning from the tropics. *Plasmodium falciparum* is responsible for virtually all cases of imported malaria that require admission to an intensive care unit (ICU), including those that die, which may be as many as 29% \[[@B1]\].

Most descriptions of the clinical spectrum of severe malaria disease come from countries where the disease is endemic and predominantly affects young children. In these settings, adults are assumed to develop some degree of immunity to the disease, although this is rapidly lost if they move away from an endemic area \[[@B2]\]. The precise mechanisms that contribute to this acquired immunity remain poorly understood \[[@B2]\] and there is no agreed definition of 'immunity' in studies of imported malaria. Relatively few data have been published concerning the pattern of disease among adult patients with severe imported malaria. The aim of this study was to review all published series of falciparum malaria requiring admission to an ICU in resource-rich countries to determine the reasons for admission, complication and case fatality rates and the frequency of concomitant bacterial sepsis, which has been reported to be very high among African children with the disease \[[@B3]\].

Methods
=======

Search method
-------------

PubMed was searched for any papers published. Combinations of the following search terms were used: "malaria", "falciparum", "ITU", "ICU", "intensive care", "imported" and "non-endemic". The abstracts of all these papers were reviewed for eligibility by MM. The bibliographies of eligible articles were screened to identify any other relevant publications.

Study selection
---------------

Papers were included only if they reported data on the care and outcome of adult (aged ≥18 years) patients with imported malaria requiring admission to ICU. For pragmatic reasons case series of fewer than ten patients were excluded.

Data extraction
---------------

Data from each paper were extracted on to a standardized form. Where possible, data were recorded about demographics, region of travel, use of anti-malarial chemoprophylaxis, the management of malaria, including requirements for organ support, complications of malaria, rates and nature of bacterial co-infection and outcome.

Statistical analyses
--------------------

Continuous variables were described with mean and standard deviation (SD) or with median and interquartile range (IQR) as appropriate. Categorical data were described with numbers and per cent. All analyses were carried out using Stata 10 (Statacorp).

Results
=======

Literature search
-----------------

The literature search identified 61 papers, 13 of which were included (Figure [1](#F1){ref-type="fig"}) \[[@B1],[@B4]-[@B15]\]. Forty-eight were excluded; 22 were not published in English, 11 were not primary research articles, four reported only on paediatric cases and 11 were short case series that included fewer than ten patients. The 13 studies reviewed included a total of 1,001 patients over a 41-year period (Table [1](#T1){ref-type="table"}). All 13 were retrospective cohort studies; 11 reported patients treated in Europe; the other two were from Singapore and South Africa. Four studies included some patients with severe malaria that were not admitted to an ICU and seven included some aged under 18 years (n = 15 in total); where possible, individual patient data were used to exclude these from further analyses. Where it was not possible to exclude paediatric patients from the analysis, this is made that clear.
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###### 

Included studies

         **Study**           **Country**     **Time period**      **Study type**       **Number of patients**
  ------------------------ ---------------- ----------------- ----------------------- ------------------------
     Badiaga \[[@B4]\]          France          1996-2002          Single centre               37^a^
     Blumberg \[[@B1]\]      South Africa       1993-1994          Single centre               23^b^
   Bruneel 2003 \[[@B5]\]       France          1988-1999          Single centre                188
   Bruneel 2010 \[[@B6]\]       France          2000-2006      Multi centre (n = 45)            400
      Gachot \[[@B7]\]          France          1988-1993          Single centre                 40
     Gonzalez \[[@B8]\]         Spain           1991-2007          Single centre               20^c^
       Khoo \[[@B9]\]         Singapore         1994-1997          Single centre               19^d^
      Marks \[[@B10]\]      United Kingdom      1994-2010          Single centre                124
     Nüesch \[[@B11]\]       Switzerland        1970-1992      Multi centre (n = 2)              23
     Salord \[[@B12]\]          France          1985-1990          Single centre               19^e^
     Santos \[[@B13]\]          Spain           1990-2011          Single centre               56^f^
     Schwake \[[@B14]\]        Germany          1996-2003          Single centre                 13
   Thierfelder \[[@B15]\]    Switzerland        1994-2004          Single centre               38^g^

^a^Two paediatric cases excluded.

^b^Five paediatric cases excluded where possible.

^c^At least one patient was aged under 18.

^d^One paediatric case excluded.

^e^Two paediatric cases excluded from further analyses where possible.

^f^Three paediatric cases excluded from further analyses where possible.

^g^At least one patient was aged under 18 and one patient had Vivax infection: Individual patient data were not available therefore these patients could not be excluded from further analyses.

Epidemiology
------------

Of the 1,001 patients, men aged between 30 and 50 made up the largest group (Table [2](#T2){ref-type="table"}). In studies in which ethnicity was reported (nine studies, 916 patients), most were originally from non-endemic countries (59%, range 49-100%). Except for the paper from Singapore \[[@B9]\], *P. falciparum* was almost always acquired during travel to sub-Saharan Africa. Use of appropriate anti-malarial chemoprophylaxis was poor (\<20%) in all studies.

###### 

Demographics and epidemiology

         **Study**          **Male**   **Median age (Median + IQR, or Mean ± SD)**   **Semi immune**^**a**^   **Acquired in Africa**   **Adequate chemoprophylaxis**
  ------------------------ ---------- --------------------------------------------- ------------------------ ------------------------ -------------------------------
          Badiaga             73%                    45 (IQR 29-55)                           17%                      100%                         5%
          Blumberg            61%                  38 (IQR 30-48 · 5)                     Not reported                 100%                    Not reported
   Bruneel 2003 \[[@B5]\]     63%          38 (no IQR available, range 14-74),                49%                      94%                          4%
   Bruneel 2010 \[[@B6]\]     70%          42 · 8 ± 15^b^ + 55 · 6 ± 14 · 2^c^                40%                      96%                          16%
           Gachot             58%         39 · 2 ± 3 · 7^d^ + 38 · 3 ± 0 · 2^e^               35%                      95%                     Not reported
          Gonzalez            75%          44 (No IQR available, range 16-68)                  0%                      95%                          0%
            Khoo              89%               38 (IQR 29 · 5 -- 50 · 5)                 Not reported                 21%                          0%
           Marks              63%                    46 (IQR 35-55)                           45%                      94%                          1%
           Nüesch             83%                  42 (IQR 37 · 5-51)                     Not reported             Not reported                     9%
           Salord             74%                37 (IQR 28 · 5-42 · 5)                   Not reported                 95%                          0%
           Santos             80%                    42 (IQR 33-50)                           51%                      95%                          2%
          Schwake             72%                  38 · 4 ± 11 · 4^f^                         28%                      88%                          20%
        Thierfelder           50%         38 (no IQR available, range 16-71)^g^               49%                      82%                     Not reported

^a^Definitions of Semi-Immune provided in Additional file [1](#S1){ref-type="supplementary-material"}.

^b^Survivors ^c^Non-Survivors.

^d^Patients with Acute Lung Injury ^e^Patients without Acute Lung Injury.

^f^Not all patients in the study were admitted to ICU - Demographic data for only those patients admitted to ICU was not available.

^g^Not all patients in the study were admitted to ICU - Demographic data for only those patients admitted to ICU was not available. Individual patient data were not available therefore it was not possible to exclude the paediatric cases from these figures.

The definition of "immunity" to malaria varied between studies (Additional file [1](#S1){ref-type="supplementary-material"}). Individual patient data was not available to allow a consistent definition of immunity to be applied across all studies.

Treatment of malaria and ICU care
---------------------------------

Quinine was the usual first-line drug in all 13 studies (Table [3](#T3){ref-type="table"}). Use of artemisinins was reported in only one paper \[[@B10]\]. In the study by Nüesch \[[@B11]\], chloroquine with or without sulphadoxine/pyrimethamine was the first-line anti-malarial treatment before 1987. In those studies limited exclusively to patients admitted to ICU, the proportion of patients requiring renal replacement therapy, mechanical ventilation and inotropic support were 22% (95% CI 19-25%), 34% (95% CI 32-38%) and 27% (95% CI 24-30%), respectively. Only two small studies (n = 52) provided adequate detail to assess requirements of individual patients for multiple organ support. In these two studies 44% of patients required at least two organ support. Six studies reported the use of exchange transfusion in a median of 25% of patients (IQR 18-29%). The median length of stay on ICU ranged from --four to 11 days.

###### 

Management of patients

         **Study**                  **Quinine**           **Artemisinins**   **Renal replacement therapy**   **Invasive ventilation**   **Inotropic support**   **Exchange transfusion**   **Length of ICU admission (Median days, IQR)**
  ------------------------ ----------------------------- ------------------ ------------------------------- -------------------------- ----------------------- -------------------------- ------------------------------------------------
          Badiaga                      100%                      0%                  Not reported                  Not reported             Not reported              Not reported                            4 (2-14)
          Blumberg                     100%                      0%                       48%                          57%                       57%                      17%                                 8 (5-13)
   Bruneel 2003 \[[@B5]\]              100%                      0%                       15%                          43%                       13%                       0%                             8 (4-13) 2 (1-4)
   Bruneel 2010 \[[@B6]\]               98%                 Not reported                  20%                          29%                       27%                       0%                             4 (2-7) 5 (3-8)
           Gachot                      100%                      0%                  Not reported                      23%                  Not reported              Not reported                     11 (No IQR available)
          Gonzalez                     100%                      0%                       40%                          50%                  Not reported                  30%                                 5 (3-12)
            Khoo                       100%                      0%                       47%                          42%                       37%                      32%                              5 +/- 4(Mean)
           Marks                        99%                     17%                       35%                          37%                       35%                      27%                                 10 (7-9)
           Nüesch           15% (Pre-1987) 100% (1987-)          0%                       9%                           26%                       22%                      22%                                 6 (2-28)
           Salord                       89%                      0%                       5%                           42%                       11%                      16%                               Not reported
           Santos                      100%                      0%                       14%                          37%                       49%                  Not reported                       4 (2-12) 8 (3-27)
          Schwake                      100%                      0%                       7%                            5%                       8%                   Not reported                            5 (3-6)
        Thierfelder                Not reported             Not reported             Not reported                  Not reported             Not reported              Not reported                          Not reported

Bacterial co-infections
-----------------------

The rate of community-acquired bacterial co-infection was reported in seven studies (n = 855, including four paediatric cases) with an overall prevalence of 8% (n = 66; range 0-13%). Pneumonia was the most common community-acquired co-infection occurring in 28 (3%) cases. Bacteraemia, defined as a positive blood culture within 48 hours of admission, was found in 25 (3%) cases; most of these (18, (72%)) were caused by gram-negative bacteria.

Complications of *Plasmodium falciparum* infection
--------------------------------------------------

Definitions of complications, including hyperparasitaemia, varied between studies (Additional file [2](#S2){ref-type="supplementary-material"}). The frequency with which these complications occurred is shown in Table [4](#T4){ref-type="table"}.

###### 

Complications

         **Study**          **Hyper-Parasitaemia**   **Acidosis**     **AKI**      **Impaired consciousness**    **Shock**     **Coagulopathy**     **ARDS**     **Hypoglycaemia**   **Jaundice**   **Seizures**   **Anaemia**    **Haema globinuria**   **Bacterial Co-Infection**   **Mortality**
  ------------------------ ------------------------ -------------- -------------- ---------------------------- -------------- ------------------ -------------- ------------------- -------------- -------------- -------------- ---------------------- ---------------------------- ---------------
          Badiaga                    78%                  8%            35%                   24%                   19%               8%              24%               0%               62%            11%             0%                14%                   Not reported               8%
          Blumberg                   79%                 36%            61%                   39%                   46%              14%              46%               11%              39%            11%            21%                 0%                   Not reported               29%
   Bruneel 2003 \[[@B5]\]            21%                 10%            25%                   18%                   11%              12%               5%               2%               27%             1%             8%                 1%                       10%                    5%
   Bruneel 2010 \[[@B6]\]            64%                 18%            34%                   26%                   24%               3%              25%               3%               52%             7%             4%                 6%                        8%                    11%
           Gachot                Not reported        Not reported       55%                   38%                   25%              35%              30%               10%          Not reported   Not reported        8%            Not reported                  13%                    13%
          Gonzalez                   60%                 30%            35%                   20%                   25%              55%              10%               15%              90%            10%             0%                 5%                        0%                    25%
            Khoo                     45%                 35%            45%                    0%                   30%              30%               5%               0%               75%            15%            20%            Not reported              Not reported               15%
           Marks                     66%                 55%            44%                   35%                   27%              11%              19%               4%               69%             7%             4%                 0%                        5%                    4%
           Nüesch                    65%             Not reported       26%                   17%                    9%               4%               4%          Not reported           4%        Not reported       13%            Not reported                  13%                    17%
           Salord                    58%             Not reported       32%                   47%               Not reported     Not reported         26%          Not reported          42%            16%        Not reported       Not reported              Not reported               0%
           Santos                    78%                 39%            53%                   19%                   49%              22%              37%               31%              46%        Not reported        0%            Not reported                   3%                    15%
          Schwake                Not reported            31%            38%                   23%                   38%              31%              15%               23%          Not reported        0%             0%            Not reported              Not reported               0%
        Thierfelder              Not reported        Not reported   Not reported          Not reported          Not reported     Not reported     Not reported     Not reported      Not reported   Not reported   Not reported       Not reported              Not reported               0%

Ten studies (n = 918, including 14 paediatric cases) reported the presence of hyperparasitaemia, which was seen in 523 (57%) patients, using a cut-off of 2% (95% CI 54-60%). When only studies using a cut-off of \>5% were analysed, the prevalence of hyperparasitaemia was 44% (95% CI 39-49%).

Twelve studies (n = 971, including 14 paediatric cases) reported the presence of AKI, which was seen in 350 patients (36%) (95% CI 33-39%). The proportion of patients with acute kidney injury (AKI) did not differ significantly between studies that defined this as both oliguria and elevated creatinine and those studies that used only an elevated creatinine (40 *vs* 34%, p = 0 · 1280) to define AKI.

Twelve studies (n = 971, including 14 paediatric cases) reported the presence of acute respiratory distress syndrome (ARDS), which was seen in 301 patients (31%; 95% CI 28-34%). Two studies (n = 161) \[[@B6],[@B10]\] reported both complications at admission and complications that developed during the ICU stay; ARDS was present at admission in three (2%) and developed later in a further 32 (20%).

Ten studies (n = 952, including 12 paediatric cases) reported the presence of impaired consciousness, used as a proxy for cerebral malaria, which was seen in 238 patients overall (25%; 95% CI 22-28%).

Five studies (n = 624) reported the total number of complications that occurred per patient. The mean number of complications seen was 2.86% (95% CI 2.81-2.91%). Individual patient data was not available to assess if particular combinations of complications occurred with an increased frequency.

WHO defines severe malaria using a range of other criteria that include: acidosis, coagulopathy, hypoglycaemia, jaundice, and anaemia. The rates of these complications, where available, are shown in Table [4](#T4){ref-type="table"}.

Case fatality rates were reported in all 13 studies. The overall case fatality rate was 9% (95% CI 8-11%) but a case fatality rate of over 15% was reported in four studies.

Conclusions
===========

This is the first review of imported falciparum malaria among adults who were sufficiently unwell to require admission to ICU. The review supports four important conclusions. First, hyperparasitaemia, however this is defined, is not a feature in almost 50% of patients; second, up to 40% of these patients were originally from or still resident in a malaria-endemic region and may therefore be assumed to have at least partial immunity to the disease; third, co-infection with community-acquired gram-negative bacteraemia is uncommon among adults; and, finally, the case fatality rate for severe imported malaria in ICU is in the region of 10%.

AKI, ARDS and cerebral malaria were all common. Invasive ventilation was required in 22% and renal replacement therapy was required in approximately 22%. Hyperparasitaemia, which is often used as a proxy for severe falciparum, was seen in only 57% of subjects when a cut-off of ≥2% was used. When using a definition of ≥5% parasitaemia, which the WHO recommends as the criterion for severe disease in endemic areas, this proportion fell to 44%. Clinicians would be well advised not to rely on parasite count as the only indicator of severe disease.

Gram-negative bacteraemia, classically with non-typhoidal *Salmonellae*, is a well recognized complication of malaria in children \[[@B3]\], occurring in up to 20%. Recent studies have suggested that dysfunctional granulocyte mobilization may be responsible for this \[[@B16]\]. While 8% of patients had a presumed community-acquired bacterial co-infection, usually pneumonia, at admission, only 25 (3%) had culture-positive, gram-negative bacteraemia. Previous prescription of antibiotics may have caused some bias and a lower yield but it is possible that this reflects a difference in the pathophysiology of severe malaria in adults compared to children.

The overall case-fatality rate was 9% although one study \[[@B1]\] reported a rate as high as 29%. Quinine was the most commonly used anti-malarial agent in all 13 studies. Artesunate has been shown to significantly reduce case fatality from severe malaria in both Southeast Asia and Africa \[[@B17],[@B18]\]. Only one of these studies \[[@B10]\] included patients treated with artemisinins, but as these drugs become more widely available the case fatality from severe imported malaria may decline.

This review has several weaknesses. A number of studies that were not published in English were excluded and it is possible that this may have had an effect. Most of the included studies were from Europe and the conclusions may not be relevant to other settings where imported malaria is seen. In particular, indications for ICU admission are likely to have varied both between the study sites and over the period that the studies were conducted, which may partially explain the spectrum of disease severity and outcomes seen. Individual patient data were often unavailable, which meant paediatric cases could not reliably be excluded, although there were only 15 of these. For the same reasons, it was not possible to analyse temporal trends in case fatality rates or perform a detailed meta-analysis of risk factors associated with mortality. However, the review includes all series of more than ten patients published in English over more than 40 years and provides important insights into the management of this relatively uncommon disease.

It is noteworthy that no case series from North America were included in the current paper. In 2011 the United States reported 1,925 cases of America of which 183 were reported to have severe disease \[[@B19]\]. Given the significantly larger population of the United States, compared to the other countries represented in this paper, it is possible that no American centre sees a sufficiently large enough number of cases to inform a study of severe malaria in the USA.

The overall case fatality rate of 9% may not reflect modern practice. Management of ARDS has improved considerably in recent years and newer strategies for fluid resuscitation, in particular, may reduce the incidence of both multi-organ failure and long-term disability \[[@B20]\]. Similarly, optimizing fluid management for patients with ARDS may reduce pulmonary capillary leak and subsequently the length of time that patients require on ICU \[[@B21]\]. Greater awareness of what constitutes AKI \[[@B22]\] may also result in a better outcome. Each of these factors, as well as improved antimicrobial protocols, management of shock and acidosis and increasing use of artemisinins, may further reduce the case fatality associated with severe imported malaria in the future.
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